Target intelligence / Profile preview

Keratin, type II cytoskeletal 3 (KRT3)

Target
KRT3
Molecular classification
Structural protein, Intermediate filament protein
01

Overview

Keratin, type II cytoskeletal 3 (KRT3) is a structural protein that belongs to the type II (basic) cytokeratin family and forms intermediate filaments together with keratin 12 in the corneal epithelium. It plays a critical role in providing resilience and mechanical stability to the outermost layer of the cornea, protecting the eye against mechanical and microbial insults. KRT3 expression is specific to differentiated corneal epithelial cells and is regulated by transcription factors important for ocular surface development. Mutations in the KRT3 gene are causative for Meesmann corneal dystrophy, a disorder characterized by intraepithelial microcyst formation and corneal fragility, but KRT3 itself is not a therapeutic target for drugs[1][2][3][4][5][6].

Other names
Keratin 3CK-3CK3K3Cytokeratin 3Cytokeratin-3Type-II keratin Kb3K2C3_HUMAN65 kDa cytokeratinKeratin 3, type IIKeratin, type II cytoskeletal 3
02

Mechanism of action

Not applicable (structural protein, not a common drug target)

03

Biological functions

Structural support of epithelial cellsMaintenance of corneal epithelial integrityDelineation marker in corneal epithelium
04

Disease associations

Corneal dystrophy (Meesmann corneal dystrophy)Ocular surface disease
05

Biomarkers

Marker of corneal epithelial cell differentiation

Beyond the preview

Go deeper on Keratin, type II cytoskeletal 3 (KRT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keratin, type II cytoskeletal 3 (KRT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call